CTCF and metabolic dysfunction-associated steatotic liver disease: As shown in Figure 3C, in the AML12 cell model of NAFLD, cell viability was significantly reduced, but this decreasing trend was reversed in the cells of gardenoside or si-CTCF treatment groups.